EP2405755A4 - Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires - Google Patents
Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculairesInfo
- Publication number
- EP2405755A4 EP2405755A4 EP10751135A EP10751135A EP2405755A4 EP 2405755 A4 EP2405755 A4 EP 2405755A4 EP 10751135 A EP10751135 A EP 10751135A EP 10751135 A EP10751135 A EP 10751135A EP 2405755 A4 EP2405755 A4 EP 2405755A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- metabolic
- compositions
- treatment
- methods
- cardiovascular disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15942909P | 2009-03-11 | 2009-03-11 | |
US15942709P | 2009-03-11 | 2009-03-11 | |
US15942309P | 2009-03-11 | 2009-03-11 | |
PCT/US2010/000750 WO2010104595A1 (fr) | 2009-03-11 | 2010-03-11 | Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2405755A1 EP2405755A1 (fr) | 2012-01-18 |
EP2405755A4 true EP2405755A4 (fr) | 2012-11-28 |
Family
ID=42728640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10751135A Withdrawn EP2405755A4 (fr) | 2009-03-11 | 2010-03-11 | Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2405755A4 (fr) |
WO (1) | WO2010104595A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102735782A (zh) * | 2011-04-12 | 2012-10-17 | 中国科学院长春应用化学研究所 | 一种筛选α-葡萄糖苷酶抑制剂的方法 |
WO2013016742A1 (fr) * | 2011-07-22 | 2013-01-31 | Smith Conrad Anton | Composition utilisable dans le cadre d'un traitement contre l'obésité |
US8420131B2 (en) | 2011-07-25 | 2013-04-16 | Conrad Anton Smith | Composition for obesity treatment |
CN103421003A (zh) * | 2012-05-23 | 2013-12-04 | 中国医学科学院药物研究所 | 具有调脂降血糖作用的黄连碱衍生物 |
CN103919774A (zh) * | 2013-12-20 | 2014-07-16 | 中国药科大学 | 去亚甲基小檗碱在制备降血脂药物中的应用 |
US10465229B2 (en) | 2014-05-27 | 2019-11-05 | Case Western Reserve University | System and method for detecting neural injury |
WO2015185158A1 (fr) * | 2014-06-06 | 2015-12-10 | AYDIN, Ahmet Nurettin | Composition et dispositif pour le traitement du diabète |
US11426386B2 (en) | 2014-12-05 | 2022-08-30 | Case Western Reserve University | Compositions and methods of modulating S-nitrosylation |
EP3226859A4 (fr) * | 2014-12-05 | 2018-12-12 | Case Western Reserve University | Compositions et procédés de modulation de s-nitrosylation |
US20160302451A1 (en) | 2015-04-16 | 2016-10-20 | Michael Hudnall | Medical Food for Patients with Chronic Liver Disease |
CN106692973A (zh) * | 2015-11-13 | 2017-05-24 | 深圳君圣泰生物技术有限公司 | 一种组合物及其用途、药物制剂 |
CN105560232B (zh) * | 2015-12-25 | 2017-11-28 | 东北制药集团沈阳第一制药有限公司 | 一种小檗碱与辛伐他汀的药物组合物及其用途 |
US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
EP3456328A4 (fr) * | 2016-05-10 | 2020-02-26 | Shenzhen Hightide Biopharmaceutical., Ltd. | Composition, et application et préparation pharmaceutique de cette dernière |
WO2018144911A1 (fr) | 2017-02-02 | 2018-08-09 | Golo Llc | Formulations amaigrissantes et procédés d'utilisation |
CA3076889A1 (fr) | 2017-09-25 | 2019-03-28 | Case Western Reserve University | Compositions et procedes de reduction du cholesterol serique et de pcsk9 |
CN107722000A (zh) * | 2017-11-03 | 2018-02-23 | 中国药科大学 | 9位-取代的小檗碱衍生物的制备及其医药用途 |
CN108101902B (zh) * | 2017-12-27 | 2020-05-15 | 四川大学 | 高b环小檗碱和巴马亭衍生物的合成及作为降血糖的用途 |
WO2020005938A1 (fr) | 2018-06-25 | 2020-01-02 | Case Western Reserve University | Compositions et méthodes pour traiter une lésion tissulaire |
AU2019344066A1 (en) | 2018-09-21 | 2021-04-22 | Case Western Reserve University | Aldoketo reductase inhibitors and uses thereof |
US11697807B2 (en) | 2019-09-30 | 2023-07-11 | Case Western Reserve University | Electrochemical biosensor |
WO2021067490A1 (fr) * | 2019-10-01 | 2021-04-08 | Cvi Pharmaceuticals Limited | Composés, compositions et méthodes de traitement de la nash, de la nafld et de l'obésité |
WO2021142815A1 (fr) * | 2020-01-18 | 2021-07-22 | 中国医学科学院药物研究所 | Berbérine et coptisine, ou métabolites actifs associés et application de sels associés dans un médicament destiné à la prévention et/ou au traitement d'une néphropathie à l'acide urique |
CN112138007B (zh) * | 2020-09-23 | 2021-12-28 | 广州中医药大学(广州中医药研究院) | 氧化小檗碱在制备代谢性疾病药物中的应用及包含氧化小檗碱的药物组合物 |
CN114163433B (zh) * | 2021-12-21 | 2022-11-25 | 哈尔滨医科大学 | 一种小檗碱衍生物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983003970A1 (fr) * | 1982-05-14 | 1983-11-24 | Maroko Peter R | Composes, compositions et procede de traitement permettant d'ameliorer la circulation |
WO2001095908A1 (fr) * | 2000-06-15 | 2001-12-20 | Hanwha Chemical Corporation | Derives de la protoberberine inhibant l'activite de la proteine kinase activee par mitogene |
WO2004032924A1 (fr) * | 2002-10-10 | 2004-04-22 | Jiandong Jiang | Emploi de berberine en tant que sensibilisant insulinique |
WO2006029577A1 (fr) * | 2004-09-17 | 2006-03-23 | Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences | Methodes et compositions de traitement de l'hyperlipidemie |
WO2007113748A1 (fr) * | 2006-03-30 | 2007-10-11 | Rottapharm S.P.A. | Formulation orale présentant des effets cardiovasculaires bénéfiques comprenant de la berbérine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050019435A1 (en) * | 2003-07-21 | 2005-01-27 | Jeffrey Young | Method of treating non-insulin dependent diabetes mellitus and related complications |
CN101153039B (zh) * | 2006-09-30 | 2010-12-01 | 中国科学院上海药物研究所 | 13,13a-二氢小檗碱衍生物及其药物组合物和用途 |
-
2010
- 2010-03-11 EP EP10751135A patent/EP2405755A4/fr not_active Withdrawn
- 2010-03-11 WO PCT/US2010/000750 patent/WO2010104595A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983003970A1 (fr) * | 1982-05-14 | 1983-11-24 | Maroko Peter R | Composes, compositions et procede de traitement permettant d'ameliorer la circulation |
WO2001095908A1 (fr) * | 2000-06-15 | 2001-12-20 | Hanwha Chemical Corporation | Derives de la protoberberine inhibant l'activite de la proteine kinase activee par mitogene |
WO2004032924A1 (fr) * | 2002-10-10 | 2004-04-22 | Jiandong Jiang | Emploi de berberine en tant que sensibilisant insulinique |
WO2006029577A1 (fr) * | 2004-09-17 | 2006-03-23 | Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences | Methodes et compositions de traitement de l'hyperlipidemie |
WO2007113748A1 (fr) * | 2006-03-30 | 2007-10-11 | Rottapharm S.P.A. | Formulation orale présentant des effets cardiovasculaires bénéfiques comprenant de la berbérine |
Non-Patent Citations (1)
Title |
---|
See also references of WO2010104595A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2405755A1 (fr) | 2012-01-18 |
WO2010104595A1 (fr) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2405755A4 (fr) | Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires | |
EP2120580A4 (fr) | Compositions et procédés de traitement de troubles métaboliques | |
EP2603199A4 (fr) | Compositions et méthodes utilisables en vue du traitement des maladies cardiovasculaires | |
EP2552433A4 (fr) | Compositions et procédés pour le traitement de troubles somatosensoriels | |
HK1174064A1 (zh) | 用於細胞增殖相關的疾病的方法和組合物 | |
EP2528618A4 (fr) | Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité | |
EP2406389A4 (fr) | Procédés et compositions pour des troubles liés à la prolifération cellulaire | |
EP2361089A4 (fr) | Compositions et procédés pour le traitement d une fonction altérée de l' -synucléine | |
WO2011049960A9 (fr) | Compositions et méthodes pour le traitement des troubles nasosinusiens | |
EP2542060A4 (fr) | Compositions et méthodes pour le traitement et/ou la prévention de maladies cardio-vasculaires | |
HK1152939A1 (en) | Carboxamide compounds for the treatment of metabolic disorders | |
IL215856A0 (en) | Compositions and methods for treatment of cardiovascular disease | |
HK1166305A1 (zh) | 用於治療炎症的組合物及方法 | |
IL218212A0 (en) | Therapeutic methods and compositions | |
SI2300614T1 (sl) | Metode in sestavki za zdravljenje mitohondrijskih motenj | |
IL223286A0 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
ZA201107449B (en) | Compounds for the treatment of metabolic disorders | |
ZA201107446B (en) | Compounds for the treatment of metabolic disorders | |
ZA201107445B (en) | Compound for the treatment of metabolic disorders | |
ZA201203002B (en) | Compositions and methods for treating inflammatory disorders | |
WO2012021287A9 (fr) | Procédés pour le traitement et la prévention de maladies métaboliques | |
EP2405747A4 (fr) | Compositions et méthodes de traitement et prévention de maladies cardiovasculaires | |
EP2675275A4 (fr) | Compositions et méthodes utilisables en vue du traitement de l'obésité et des troubles associés | |
EP2285398A4 (fr) | Procédés et compositions pour le traitement de l obésité | |
HU0900231D0 (en) | Compositions for the treatment of allergic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111010 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20121025 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 9/12 20060101ALI20121019BHEP Ipc: A61K 31/4741 20060101AFI20121019BHEP Ipc: A61P 3/04 20060101ALI20121019BHEP Ipc: A61P 3/06 20060101ALI20121019BHEP Ipc: A61K 45/06 20060101ALI20121019BHEP Ipc: A61P 3/10 20060101ALI20121019BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130524 |